Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-emptive Azacitidine and DLI Following Allogeneic HSCT for High Risk AML and MDS
NCT01541280Phase 2Completed
- Sponsor
- CHU de Nantes
- Start
- Nov 2011
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine, donor lymphocytes in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by CHU de Nantes. Started Nov 2011; status: completed.
02
Drugs
azacitidinedonor lymphocytes
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01541280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01541280.